🇺🇸 FDA

Intelligence · Clinical Pipeline

PARItec Pipeline

All ClinicalTrials.gov programs at PARItec — phase, modality, and trial IDs.

Programs
248

Quick answer

PARItec has 248 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  2. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  3. MaaT013, Placebo de MaaT013 - Major ingredients: Calcium carbonate; Xanthan gum; Alimentary colorant; E150d: caramel color; HCl;Purified water

    Pari Pharma GmbH

    Melanoma

    phase 2 small molecule active

    1 trial

  4. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  6. Ofev 100 mg soft capsules, Ofev 150 mg soft capsules

    Pari Pharma GmbH

    Adult patients aged 18 and over with unicentric hyalino-vascular Castleman's disease

    phase 2 small molecule active

    1 trial

  7. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  8. Oxbryta 500 mg film-coated tablets

    Pari Pharma GmbH

    sickle cell disease

    phase 2 small molecule active

    1 trial

  9. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  10. PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Minimal Change Nephrotic Syndrom

    phase 2 small molecule active

    1 trial

  11. PREDNISONE, PREDNISOLONE, BOSENTAN

    Pari Pharma GmbH

    Newly diagnosed or relapsing Giant-cell arteritis

    phase 2 small molecule active

    1 trial

  12. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  13. Peptide A49 associated to melanin, Peptide A52 associated to melanin, Litenimod solution

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  14. Placebo d'amiloride, AMILORIDE, AMILORIDE

    Pari Pharma GmbH

    Patients treated with lithium carbonate for a bipolar disorder treated for at least 5 years and with a urine concentration defect.

    phase 2 small molecule active

    1 trial

  15. Placebo de macitentan 10 mg, MACITENTAN

    Pari Pharma GmbH

    Inoperable Chronic thromboembolic pulmonary hyperTension, Pneumology

    phase 2 small molecule active

    1 trial

  16. Placebo of leflunomide, Arava 20 mg film-coated tablets, Mycophenolate mofetil Teva 500 mg film-coated tablets, Placebo of mycophenolate mofetil, Placebo of hydroxychloroquine, PLAQUENIL 200 mg, comprimé pelliculé

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  17. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  18. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  19. RIFAMPICIN , TEDIZOLID PHOSPHATE, ISONIAZID , ETHAMBUTOL , PYRAZINAMIDE , RIFAMPICIN, PYRAZINAMIDE AND ISONIAZID, LINEZOLID

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  20. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  21. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  22. RoActemra 162 mg solution for injection in pre-filled syringe., Humira 80 mg solution for injection in pre-filled pen

    Pari Pharma GmbH

    Severe uveitis of Behçet’s disease

    phase 2 small molecule active

    1 trial

  23. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  24. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  25. SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN

    Pari Pharma GmbH

    recurrent primary supratentorial malignant brain tumors in children

    phase 2 small molecule active

    1 trial

  26. Sucrose octaacetate [NF], SODIUM CHLORIDE, METHYLPREDNISOLONE VIATRIS 1 g, poudre pour solution injectable (I.V.), LIQUID PREDNISONE

    Pari Pharma GmbH

    IDIOPATHIC PULMONARY FIBROSIS

    phase 2 small molecule active

    1 trial

  27. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  28. Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis

    Pari Pharma GmbH

    Amyotrophic lateral Sclerosis

    phase 2 other active

    1 trial

  29. Trecondi 1 g powder for solution for infusion, FLUDARABINE PHOSPHATE, THIOTEPA, Trecondi 5 g powder for solution for infusion

    Pari Pharma GmbH

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  30. XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  31. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  32. A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants with Advanced Rod Cone Dystrophy

    Pari Pharma GmbH

    End-stage rod-cone dystrophy

    phase 1 other active

    1 trial

  33. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  34. Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  35. HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  36. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  37. MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension

    Pari Pharma GmbH

    Familial Hemophagocytic Lymphohistiocytosis (FHL)

    phase 1 small molecule active

    1 trial

  38. SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  39. Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  40. -, -, SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Pari Pharma GmbH

    Pyelonephritis, Kidney Transplant recipients

    approved small molecule active

    1 trial

  41. AMOXICILLIN

    Pari Pharma GmbH

    Adults diagnosed with lower limbs erysipelas

    approved small molecule active

    1 trial

  42. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  43. AMPICILLIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , OFLOXACIN , MOXIFLOXACIN , AZITHROMYCIN , LEVOFLOXACIN , AMOXICILLIN , PRISTINAMYCIN , ERYTHROMYCIN , CIPROFLOXACIN , CLARITHROMYCIN

    Pari Pharma GmbH

    Community acquired pneumonia (CAP)

    approved small molecule active

    1 trial

  44. BILINDA GYNIAL 0,03 mg/2 mg Filmtabletten, Selina Gynial 0,03 mg/0,15 mg Filmtabletten

    Pari Pharma GmbH

    Hormonal contraception

    approved small molecule active

    1 trial

  45. CEFAZOLIN

    Pari Pharma GmbH

    Infection prophylaxis

    approved small molecule active

    1 trial

  46. DONEPEZIL, DONEPEZIL

    Pari Pharma GmbH

    Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease

    approved small molecule active

    1 trial

  47. Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Crohn’s disease

    approved small molecule active

    1 trial

  48. MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM

    Pari Pharma GmbH

    Pyogenic liver abscess

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does PARItec have?

248 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.